Q-omics provides the consensus-scored LINC01567 profile across patient tissues and cancer cell-line models. LINC01567 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, LINC01567 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, LINC01567 RNA expression shows 8,784 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight COAD, LUSC, and SARC as cancer lineages where LINC01567 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01567 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01567 survival associations across molecular data types. LINC01567 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01567 RNA expression–survival associations across cancer types. High LINC01567 expression shows unfavorable associations in COAD, PAAD and THYM, but favorable associations in BLCA, HNSC and UCEC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for LINC01567 RNA expression.
This table summarizes LINC01567 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01567. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01567 shows lower tumor expression in BRCA and higher tumor expression in LUSC and LUAD. The LUSC box plot shows higher LINC01567 RNA expression in tumor versus normal tissue (log2 FC = +0.034, t-test p = .002).
This table shows molecular features associated with LINC01567 in patient tissues and cancer cell lines. In patient samples, LINC01567 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC01567 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY.
